Abstract
Background, objectives and methods DIAPAsOn was a 6-month prospective observational multicenter study in the Russian Federation that examined adherence to a preparation of highly purified omega-3 polyunsaturated fatty acids (OMACOR) in adult patients with a history of recent myocardial infarction or endogenous hypertriglyceridemia. A full description of the study’s aims and methods has appeared in JMIR Res Protoc. A feature of DIAPAsOn was the use of a bespoke electronic patient engagement and data collection system.
Results The net average reduction from baseline in both total and low-density lipoprotein cholesterol was approximately 1 mmol/L and the net average increment in high-density lipoprotein cholesterol was 0.2±0.53 mmol/L. Mean triglyceride levels declined by ∼1.3 mmol/, from an initial level of 2.99±1.29 mmol/L to 1.67± 0.67 mmol/L. The percentage of patients with triglyceride <1.7 mmol/L rose from 13.1% at baseline to 54% at study-end.
Digital reporting of adherence was registered by 8.3% of patients (n=180) and average scores indicted poor adherence. However, clinic-based enquiry suggested high levels of adherence.
Data on health-related quality of life accrued from digitally-engaged patients identified improvements among patients reporting high adherence to study treatment, but patient numbers were small.
Conclusions The lipid and lipoprotein findings indicate that OMACOR had nominally favorable effects on the blood lipid profile. Less than 10% of patients enrolled in DIAPAsOn used the bespoke digital platform piloted in the study and the level of self-reported adherence to medication by those patients was also low. Reasons for this low uptake and adherence are unclear. Better adherence was recorded by clinical report.
Competing Interest Statement
GPA has not received any educational grants from any companies and has not received any fees or non-financial support from healthcare companies related to this study. GPA reports receiving honoraria for professional lectures at regional/national medical educational events from healthcare companies, including Abbott, Bayer, Boehringer Ingelheim, Servier. AGA has not received any educational grants from any companies and has not received any fees or non-financial support from healthcare companies related to this study. AGA reports receiving honoraria for professional lectures at regional/national medical educational events from healthcare companies, including Abbott, Bayer, Boehringer Ingelheim, Servier. FTA does not have any conflicts of interest. TVF does not have any conflicts of interest.
Clinical Trial
NCT03415152
Funding Statement
The study is supported by Abbott.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical oversight of the DIAPAsOn study was exercised by the Ethics Committee of Pirogov Russian National Research Medical University(Moscow, Russian Federation).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All relevant data are within the paper and its Supplementary Materials.
